Document is current
Any future updates will be listed below
-
Authors
Sindhwani, Shrey
Thomas, Miles
Gehlaut, Kanika
Kaur, Harveen
Haque, Waqas
Juloori, Aditya
Choudhury, Noura J. https://orcid.org/0000-0002-5980-4973
- License Information
-
More Information
Article History
Received: 16 February 2026
Accepted: 27 May 2026
First Online: 7 August 2026
Declarations
Conflicts of interest/competing interests: AJ reports consulting fees from AstraZeneca, Merck, Johnson and Johnson, Regeneron, EMD Serano, and Daiichi Sankyo. NJC reports institutional research funding from Amgen, AbbVie, Monte Rosa Therapeutics, Roche/Genetech, Merck, Harpoon Therapeutics, Janux Therapeutics, Seagen/Pfizer, Corbus, DualityBio; Honoraria from MJH Life Sciences, IDEOlogy Health; Royalties from Wolters Kluwer ( Pocket Oncology, 3 rd edition) ; consulting fees from AbbVie, Merck, Harpoon Therapeutics, Eli Lily, Amgen, Daiichi, Ideaya Biosciences, BMS, Pfizer. SS, MT, KG, HK, WH have no conflicts of interest.
Ethics approval: Not applicable.
Consent to participate: Not applicable.
Consent for publication: Not applicable.
Availability of data and material: No datasets were generated or analyzed during the current study.
Code availability: Not applicable.
Authors' contributions: SS, MT, KG, HK, WH, AJ, and NC participated in the conception, writing, editing and approval of this manuscript.
